- Home
- LFST vs SLNO Comparison
LFST vs SLNO Comparison
Compare LFST & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | SLNO |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LFST | SLNO |
|---|---|---|
| Price | $7.07 | $42.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $8.83 | ★ $112.70 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,367,570,000.00 | $98,675,000.00 |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $14.36 | $156.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.39 | N/A |
| 52 Week Low | $3.74 | $39.43 |
| 52 Week High | $8.30 | $90.32 |
Technical Indicators
Market Signals| Indicator | LFST | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 37.98 |
| Support Level | $7.02 | $41.34 |
| Resistance Level | $7.37 | $44.50 |
| Average True Range (ATR) | 0.23 | 2.65 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 15.00 | 24.28 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.